Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice.
The prophylactic and therapeutic efficacy of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine and carboxymethylcellulose [poly(I,C)-LC] was evaluated in female Swiss Webster mice against a lethal infection of Rift Valley fever virus (RVFV). Prophylactically, the best effect was obtained with 2-3 doses of 1-20 micrograms poly(I,C)-LC, which fully protected the mice in a schedule-dependent fashion against an LD100 RVFV challenge. Multiple intermittent therapeutic administration of 20 micrograms poly(I,C)-LC 24 or 48 h after infection protected 100% and 50% of the mice, respectively. When given as late as 48 h after infection, 20 micrograms poly(I,C)-LC prevented viremia, and single or multiple doses induced high levels of serum interferon that peaked 24 h after administration of the compound. As late as 48 h postinfection, a high degree of therapeutic synergism was achieved with the combined administration of poly(I,C)-LC and the antiviral compound ribavirin, using doses that were not effective alone.
M
M
Kende
D000818:Animals; D002266:Carboxymethylcellulose Sodium / Q000627:therapeutic use* / Q000031:analogs & derivatives; D004353:Drug Evaluation, Preclinical; D005260:Female; D007369:Interferon Inducers / Q000627:therapeutic use*; D007372:Interferons / Q000097:blood; D008747:Methylcellulose / Q000031:analogs & derivatives*; D051379:Mice; D011070:Poly I-C / Q000627:therapeutic use*; D011107:Polylysine / Q000627:therapeutic use* / Q000031:analogs & derivatives; D012295:Rift Valley Fever / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D012296:Rift Valley fever virus / Q000187:drug effects
D007369:Interferon Inducers; D011107:Polylysine; C019531:poly ICLC; D008747:Methylcellulose; D007372:Interferons; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C